has the phase transitions I / N\* 95.1-92.1 and N\* / Sc\* 64.6°C and the values DT (15,1) / DT (20,1) / DT (25,1) / DT (30,1) 35 / 40 / 35.5 / 31.5.

# 5 Example 15

A mixture consisting of 85% of the mixture of Example 5 and 15% of the compound

$$C_{g^{\mathsf{H}_1}}, \qquad \qquad C_{g^{\mathsf{H}_1}, \mathsf{T}} \longrightarrow CC_{g^{\mathsf{H}_1}, \mathsf{T}}$$

has the phase transitions I /N\* 99.6-96.0 and N\* / Sc\* 63.2°C and the values DT (15,1) / DT (20,1) / DT (25,1) / DT (30,1) 32.5 /30 / 28.8 / 26.

The compounds according to the invention are further illustrated by 15 Examples 16-25.

#### Example 16

4-(2-Fluoro-3-hexyloxypryridine6-yl)phenyl 5-octylthiophene-2-carboxylate

$$\mathsf{H}_{13}\mathsf{C_6}\mathsf{O} - \bigvee_{\mathsf{S}} \mathsf{C_6}\mathsf{H}_{1}$$

20

25

10

0.8 g of 4-(2-fluoro-3-hexyloxypyridin-6-yl)phenol and 0.7 g 5-octyl-thiophene-2-carboxylic acid are reacted in 100 ml of dichloromethane in the presence of 0.6 g of dicyclohexylcarbodiimide. Workup by filtration, column chromatography and recrystallization gives 1 g of colorless crystals having a melting point of 101  $^{\circ}$ C and a clearing point of 124 $^{\circ}$ C.

The following compounds are obtained in a similar manner:

# Example 17

4-(2-Fluoro-3-hexyloxypyridin-6-yl)phenyl 5-hexylthiophene-2-carboxylate having a melting point of 95°C and a clearing point of 126°C.

#### 5 Example 18

6-(4-Octyloxyphenyl)-2-fluoropyridin-3-yl 5-butylthiophene-2-carboxylate

$$\mathsf{H}_{\mathsf{1},\mathsf{1}}\mathsf{C}_{\mathsf{g}}\mathsf{O} - \bigvee^{\mathsf{N}} - \bigvee^{\mathsf{F}} \mathsf{C}_{\mathsf{d}}\mathsf{H}_{\mathsf{g}}$$

having a melting point of 86°C and a clearing point of 114°C.

# Example 19

10

15

20

25

4-(5-Decyl-4-fluoropyrimidin-2-yl)phenyl 5-butylthiophene-2-carboxylate

$$H_{21}C_{10} = N$$

#### Example 20

4-(6-Ethyl-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl hexanecarboxylate

trans-4-pentylcyclo-

$$H_sC_2$$
  $O$   $C_sH_1$ 

Phase sequence X 114 N 216 I

## Example 21

4-(6-Nonyl-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate

Phase sequence X 112 S<sub>C</sub> 124 S<sub>A</sub> 143 N 204 I

#### Example 22

4-(6-Nonyl-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-propylcyclohexanecarboxylate

Phase sequence X 111 (S<sub>C</sub> 100) S<sub>A</sub> 124 N 202 I

5

## Example 23

4-(6-Propyloxy-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate
Phase sequence X 99 N 175 I

10

15

# Example 24

4-(6-Hexyloxy-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentyl-cyclohexanecarboxylate

Phase sequence X 100 N 155

# Example 25

4-(6-Octyloxy-1,2,3,4-tetrahydroquinazolin-2-yl)phenyl trans-4-pentylcyclohexanecarboxylate
Phase sequence X 97 (Sc95) N 145 I

20

#### Example 26

4-(5-Tetradecylpyrimidin-2-yl)phenyl trans-4-pentylcyclohexane-carboxylate Phase sequence X 5552 96 S $_{\rm C}$  130 N 151 I

# 25 Example 27

4-(5-Tetradecylpyrimidin-2-yl)phenyl trans-4-hexylcyclohexanecarboxylate Phase sequence X 77 S $_2$  105 S $_C$  133 N 147 I

#### Example 28

30 4-(5-Tetradecylpyrimidin-2-yl)phenyl trans-4-heptylcyclohexanecarboxylate Phase sequence X 41 S<sub>2</sub> 108 S<sub>C</sub> 136 N 148 I

# Example 29

35

2-(4-Undecylphenyl)pyrimidin-5-yl trans-4-propylcyclohexanecarboxylate Phase sequence X 77 S<sub>A</sub> 165 N 171 I